Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
MARLBOROUGH, Mass., May 11, 2023 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended March 31, 2023 and provided a business update. Logo – https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg … Read more